{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:38:47Z","timestamp":1790289527095,"version":"4.1.0"},"reference-count":57,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and aim: Managing the therapy of patients with chronic liver diseases and comorbidities presents significant challenges for physicians and pharmacists, particularly regarding drug-induced liver damage and polypharmacy. Given the liver\u2019s central role in drug detoxification, polypharmacy in liver disease requires special attention. The aim of the review was to assess the prevalence of polypharmacy among patients with chronic liver diseases. Approach and Results: A literature search focused on randomized controlled trials, database reviews, and medical records. Review of PubMed, SCOPUS, and ScienceDirect databases identified 2578 manuscripts, however only 11 studies met the inclusion criteria. The results of studies showed that the prevalence of polypharmacy among patients with chronic liver disease can exceed 50%, and can lead to high prevalence of MRP and pDDI among those patients. Conclusions: Findings reveal a critical link between polypharmacy and adverse outcomes in chronic liver diseases, including cirrhosis, hepatitis, and non-alcoholic fatty liver disease. Individualized treatment plans, considering factors such as age, gender, comorbidities, and liver disease severity are essential. The interventions focused on mitigating MRP and reducing pDDI need to be implemented in order to reduce the potential harm of polypharmacy.<\/jats:p>","DOI":"10.3390\/jcm14176263","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:46:17Z","timestamp":1757058377000},"page":"6263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of Polypharmacy Among Patients with Chronic Liver Disease\u2014A Narrative Literature Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-8427","authenticated-orcid":false,"given":"Monika","family":"Szkultecka-D\u0119bek","sequence":"first","affiliation":[{"name":"University of Social Sciences, 00-842 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6479-3455","authenticated-orcid":false,"given":"Lucyna","family":"Bu\u0142a\u015b","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-4958","authenticated-orcid":false,"given":"Agnieszka","family":"Skowron","sequence":"additional","affiliation":[{"name":"Department of Social Pharmacy, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-2386","authenticated-orcid":false,"given":"Mariola","family":"Drozd","sequence":"additional","affiliation":[{"name":"Department of Humanities and Social Medicine, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00018-025-05744-3","article-title":"Mechanisms of drug induced liver injury","volume":"82","author":"Lykkesfeldt","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in nonalcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab. Rev."},{"key":"ref_3","first-page":"212","article-title":"Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity","volume":"3","author":"Massart","year":"2017","journal-title":"J. Clin. Transl. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.3748\/wjg.v20.i22.6821","article-title":"Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease","volume":"20","author":"Khov","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s43066-024-00381-0","article-title":"Drug-induced liver injury during the era of COVID-19 polypharmacy: A statement of account, lessons learned, and a proposed approach","volume":"14","author":"Badary","year":"2024","journal-title":"Egypt. Liver J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel (2023). American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc., 71, 2052\u20132081.","DOI":"10.1111\/jgs.18372"},{"key":"ref_10","first-page":"112","article-title":"A Comprehensive Clinical Review on Geriatric Polypharmacy","volume":"18","author":"Peter","year":"2025","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"ref_11","unstructured":"URPL (2024, October 09). Annual Report of the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products 2023, Available online: https:\/\/www.gov.pl\/web\/urpl\/raport-roczny."},{"key":"ref_12","first-page":"112","article-title":"A focus on epidemiology of drug-induced liver injury: Analysis of a prospective cohort","volume":"21","author":"Licata","year":"2017","journal-title":"Eur. Rew. Med. Pharmacol. Sci."},{"key":"ref_13","first-page":"94","article-title":"Farmakoterapia jatrogenizacyjna w medycynie paliatywnej, nie tylko w populacji senioralnej\u2014Lekcewa\u017cony problem praktyczny w 10 ods\u0142onach","volume":"18","author":"Gryglewska","year":"2024","journal-title":"Geriatria"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1177\/0960327113512860","article-title":"Female gender as a susceptibility factor for drug-induced liver injury","volume":"33","author":"Amacher","year":"2014","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/ajg.2017.215","article-title":"Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to caucasians: A randomized controlled trial","volume":"112","author":"Naga","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2005.03.017","article-title":"Enterohepatic transport of bile salts and genetics of cholestasis","volume":"43","author":"Stieger","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5604\/01.3001.0012.7200","article-title":"Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?","volume":"17","author":"Noor","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajg.2020.09.008","article-title":"Polypharmacy and drug interactions amongst cirrhotic patients discharged from a tertiary center: Results from a national quality improvement audit","volume":"21","author":"Elzouki","year":"2020","journal-title":"Arab. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Abe, J., Umetsu, R., Uranishi, H., Suzuki, H., Nishibata, Y., Kato, Y., Ueda, N., Sasaoka, S., Hatahira, H., and Motooka, Y. (2017). Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0190102"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-011-1105-5","article-title":"Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis","volume":"68","author":"Franz","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/hep4.1334","article-title":"Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention","volume":"3","author":"Hayward","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ruzicka, D.J., Tetsuka, J., Fujimoto, G., and Kanto, T. (2018). Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3148-z"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s11136-022-03090-6","article-title":"The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States","volume":"31","author":"Alrasheed","year":"2022","journal-title":"Qual. Life Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e6761","DOI":"10.1097\/MD.0000000000006761","article-title":"Multimorbidity and polypharmacy in diabetic patients with NAFLD","volume":"96","author":"Patel","year":"2017","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/jmv.24848","article-title":"Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK","volume":"89","author":"Hudson","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40801-023-00390-2","article-title":"Changing Prevalence of Medication Use in People with Cirrhosis: A Retrospective Cohort Study Using Pharmaceutical Benefits Scheme Data","volume":"10","author":"Hayward","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.jsps.2023.06.001","article-title":"Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life","volume":"31","author":"Farooq","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_30","unstructured":"Francis, P., and Navarro, V.J. (2025). Drug-Induced Hepatotoxicity. StatPearls, StatPearls Publishing."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hu, X., Liu, R., Tang, L., Mei, M., Li, Y., Tang, G., Feng, J., Chen, W., and Li, G. (2024). Physicians and hospital pharmacists\u2019 knowledge, attitudes, and practices towards polypharmacy in older patients with chronic diseases. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-80989-9"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/dmd.113.056267","article-title":"High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.32383\/farmpol\/155155","article-title":"Drug-induced liver injury (DILI)\u2014Mechanisms and diagnostic","volume":"78","author":"Piechaczek","year":"2022","journal-title":"Farm. Polska"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/cld.856","article-title":"The Origins of the Modern-Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman","volume":"15","author":"Lewis","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15114","article-title":"Drug-Induced Liver Injury: Pattern Recognition and Future Directions","volume":"10","author":"Haque","year":"2016","journal-title":"Gut Liver"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mahin, D., Lauren, M., Behnaz, J., Anees, B., Zahra, G., Julia, K., and Zia, C. (2022). Prevalence and factors associated with polypharmacy: A systematic review and meta-analysis. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03279-x"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Khezrian, M., McNeil, C.J., Murray, A.D., and Myint, P.K. (2020). An overview of prevalence, determinants and health outcomes of polypharmacy. Ther. Adv. Drug Saf., 11.","DOI":"10.1177\/2042098620933741"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s40267-022-00957-z","article-title":"Association between polypharmacy, patient-reported symptoms, and quality of life among nonalcoholic fatty liver disease patients in the United States","volume":"38","author":"Alrasheed","year":"2022","journal-title":"Drugs Ther. Perspect."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zaij, S., Maia, K.P., Leguelinel-Blache, G., Roux-Marson, C., Kinowski, J.M., and Richard, H. (2023). Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: A qualitative systematic review. BMC Health Serv. Res., 23.","DOI":"10.1186\/s12913-023-09512-6"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/hep4.1612","article-title":"Improving Medication-Related Outcomes in Chronic Liver Disease","volume":"4","author":"Hayward","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40264-020-00918-3","article-title":"Prevalence and Nature of Medication Errors and Medication-Related Harm Following Discharge from Hospital to Community Settings: A Systematic Review","volume":"43","author":"Alqenae","year":"2020","journal-title":"Drug Saf."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Elbeddini, A., Yang, L., and Aly, A. (2020). A Case-Control Study: The Impact of Unintentional Discrepancies and Pharmacist Discharge Prescription Review on 30-Day Hospital Readmission. J. Prim. Care Community Health, 11.","DOI":"10.1177\/2150132720932012"},{"key":"ref_44","first-page":"1501","article-title":"Effectiveness of a pharmacist-led quality improvement program to reduce medication errors during hospital discharge","volume":"17","author":"George","year":"2019","journal-title":"Pharm. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.32383\/farmpol\/172894","article-title":"New Medicine Service as support for medication adherence by chronically ill patients","volume":"79","author":"Dymek","year":"2023","journal-title":"Farm. Polska"},{"key":"ref_46","unstructured":"Skowron, A., Drozd, M., Brukiewicz, P., Dymek, J., Go\u0142da, A., and \u017bmudzka, E. (2025, August 23). Zalecenia Dotycz\u0105ce Post\u0119powania u Os\u00f3b Obj\u0119tych \u015awiadczeniem Konsultacja w Przypadku Drobnej Dolegliwo\u015bci. Naczelna Izba Aptekarska, Warszawa. Available online: https:\/\/www.nia.org.pl\/wp-content\/uploads\/2024\/01\/Konsultacja_w_przypadku_drobnej_dolegliwosci_2024-01-30.pdf."},{"key":"ref_47","unstructured":"Drozd, M., Skowron, A., Karolewicz, B., Bu\u0142a\u015b, L., Machalska, J., Dymek, J., Go\u0142da, A., and Jachowicz, M. (2025, August 23). Wytyczne Polskiego Towarzystwa Farmaceutycznego Dotycz\u0105ce Prowadzenia \u015awiadczenia Zdrowotnego\u2014Przegl\u0105d Lekowy. Polskie Towarzystwo Farmaceutyczne, Warszawa. Available online: https:\/\/ptfarm.pl\/pub\/File\/Sekcje\/Sekcja_opieki_farmaceutycznej\/WYTYCZNE_przeglad_lekowy_net.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/ajhp\/zxaa012","article-title":"Real-world evidence on impact of a pharmacist-led transitional care program on 30- and 90-day readmissions after acute care episodes","volume":"77","author":"Eom","year":"2020","journal-title":"Am. J. Health Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2119346","DOI":"10.1001\/jamanetworkopen.2021.19346","article-title":"Interventions to Improve Communication at Hospital Discharge and Rates of Readmission","volume":"4","author":"Becker","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.japh.2019.01.005","article-title":"Improving care transitions through medication therapy management: A community partnership to reduce readmissions in multiple health-systems","volume":"59","author":"Heaton","year":"2019","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40261-019-00797-2","article-title":"Systematic Review and Meta-analysis of Pharmacist-Led Transitions of Care Services on the 30-Day All-Cause Readmission Rate of Patients with Congestive Heart Failure","volume":"39","author":"McKay","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ijpp\/riaa004","article-title":"A rapid review and narrative synthesis of hospital to community pharmacy transfer of care services in England","volume":"29","author":"Nazar","year":"2021","journal-title":"Int. J. Pharm. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bcp.13839","article-title":"Ensuring continuity of patient care across the healthcare interface: Telephone follow-up post-hospitalization","volume":"85","author":"Odeh","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/13561820.2018.1513466","article-title":"Impact of an interprofessional transition of care service on 30-day hospital reutilizations","volume":"33","author":"Otsuka","year":"2019","journal-title":"J. Interprof. Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/bcp.14349","article-title":"Effectiveness of a multicomponent pharmacist intervention at hospital discharge for drug-related problems: A cluster randomised cross-over trial","volume":"86","author":"Pourrat","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.japh.2018.11.005","article-title":"Reductions in 30-day readmission, mortality, and costs with inpatient\u2013to\u2013community pharmacist follow-up","volume":"59","author":"Wright","year":"2019","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_57","unstructured":"G\u00f3recka, A., Drozd, M., Olejniczak-Rabinek, M., Bu\u0142a\u015b, L., Jasi\u0144ska-Stroschein, M., Machalska, J., Matschay, A., and Waszyk-Nowaczyk, M. (2025, August 23). Wytyczne wykonywania \u015awiadczenia Zdrowotnego\u2014Poszpitalna Opieka Farmaceutyczna (POF) Polskie Towarzystwo Farmaceutyczne; Warszawa. Available online: https:\/\/ptfarm.pl\/pub\/File\/opieka_farmaceutyczna\/Poszpitalna%20Opieka%20Farmaceutyczna\/Wytyczne_POF_net.pdf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:49Z","timestamp":1760035189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":57,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14176263"],"URL":"https:\/\/doi.org\/10.3390\/jcm14176263","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}